The aim of the study was to evaluate the use of 18F-fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) in the follow-up and clinical management of ovarian cancer patients after therapy.
A total of 152 ovarian cancer patients who had undergone therapy were evaluated. Clinical information, CA-125 levels, and traditional imaging findings were analyzed. According to the indication for PET/CT the patients were divided into five groups for assessing the role of 18F-FDG PET/CT in the clinical management of ovarian cancer patients after therapy. A comparison was made between the PET/CT findings and the results of clinical follow-up.
Of the 152 patients, 137 had follow-up results and 15 were lost to follow-up. A total of 105 patients were found to have recurrent tumor and 32 were found to be disease-free after long-term follow-up. The diagnostic sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 98.3, 91.2, 96.8, 97.5, and 93.9%, respectively. PET/CT was especially useful in patients when indications were to diagnose suspected recurrence, assess disease progression, and evaluate therapeutic response.
PET/CT has been proven to be extremely valuable in the evaluation of patients with recurrent ovarian cancer and is particularly helpful in guiding treatment planning.
aPET-CT Center, Department of Radiological Diagnosis and Therapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
bDepartment of Radiology, USC Keck School of Medicine, Los Angeles, California, USA
Correspondence to Lin-jun Tong, MD, PET-CT Center, Department of Radiological Diagnosis and Therapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd., Shanghai 200127, China Tel/fax: +86 21 50890497; e-mail: email@example.com
Received March 5, 2013
Accepted October 21, 2013